Fundraising FoxAminex Therapeutics
Kenmore, US · Washington corporation
Find your way into Aminex Therapeutics
Sign up to see every warm intro you have to Aminex Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aminex Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MB
Mark BurnsFounder, President & CSOMark Burns founded Aminex Therapeutics after licensing oncology immunomodulator technology from MediQuest Therapeutics, where he held development leadership roles. He has led drug development from preclinical through early-stage clinical phases, holds 19 issued U.S. patents, and has published 28 peer-reviewed scientific articles.
SH
Stacy HockNamed on SEC filing
RU
Roger UlrichNamed on SEC filing
TG
Thomas GrahamNamed on SEC filing
RR
Board
JR
John RoslingBoard director
DM
Donald MowatBoard director
DA
Deyaa AdibBoard director
JS
James SkaggsBoard director
JM
Jeffrey MillerBoard director
DM
David MeeksBoard director
DD
Don DyerBoard director
Reported raises · per SEC filings
Form D private placements$34.5M disclosed across 6 rounds · 2014–2022
▶$15.1MraisedDec 2025 · 162 investors · BiotechnologyRule 506(b)
▶$15.1MraisedDec 2025 · 162 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Deyaa AdibDirector
- James SkaggsDirector
- Mark BurnsExecutive Officer, Director
- Jeffrey MillerDirector
- David MeeksDirector
- Don DyerDirector
- Offering amount
- $30M
- Amount sold
- $15.1M
- First sale
- Oct 2022
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$6.3MraisedAug 2021 · 97 investors · BiotechnologyRule 506(b)
▶$6.3MraisedAug 2021 · 97 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Larry RichardsExecutive Officer
- James SkaggsExecutive Officer, Director
- Mark BurnsExecutive Officer, Director
- Roger UlrichDirector
- Jeff MillerDirector
- Rhonda RhyneDirector
- Stacy HockDirector
- Offering amount
- $9.1M
- Amount sold
- $6.3M
- Minimum investment
- $2
- First sale
- Aug 2021
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$2.9MraisedAug 2020 · 96 investors · BiotechnologyRule 506(b)
▶$2.9MraisedAug 2020 · 96 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark BurnsExecutive Officer, Director
- James SkaggsExecutive Officer, Director
- Stacy HockDirector
- Roger UlrichDirector
- Rhonda RhyneDirector
- Jeff MillerDirector
- Offering amount
- $3M
- Amount sold
- $2.9M
- First sale
- Jul 2020
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$8.3MraisedJun 2018 · 96 investors · BiotechnologyRule 506(b)
▶$8.3MraisedJun 2018 · 96 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stacy HockDirector
- Mark BurnsExecutive Officer, Director
- Roger UlrichDirector
- Thomas GrahamExecutive Officer, Director
- Jeff MillerDirector
- Rhonda RhyneDirector
- James SkaggsExecutive Officer, Director
- Offering amount
- $14.2M
- Amount sold
- $8.3M
- First sale
- May 2018
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$410KraisedNov 2014 · 3 investors · BiotechnologyRule 506(b)
▶$410KraisedNov 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John RoslingDirector
- Mark BurnsExecutive Officer, Director
- Jeff MillerDirector
- James SkaggsDirector
- Thomas GrahamExecutive Officer, Director
- Offering amount
- $2.4M
- Amount sold
- $410K
- First sale
- Oct 2014
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$1.6MraisedJul 2014 · 22 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJul 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark BurnsExecutive Officer, Director
- Thomas GrahamExecutive Officer, Director
- John RoslingDirector
- Donald MowatDirector
- James SkaggsExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.6M
- First sale
- Jun 2014
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Aminex Therapeutics raised?
- Aminex Therapeutics has disclosed $34.5M raised across 6 rounds.
- Where is Aminex Therapeutics headquartered?
- Aminex Therapeutics is headquartered in Kenmore, US.